NCT05644561 2026-04-17
Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
Alexion Pharmaceuticals, Inc.
Immunovant Sciences GmbH
AstraZeneca
Amgen
UCB Pharma
Cabaletta Bio
Regeneron Pharmaceuticals
Alexion Pharmaceuticals, Inc.
Intuitive Surgical
argenx
argenx
Dianthus Therapeutics
Cartesian Therapeutics